The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure

Trial Profile

The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Capsaicin (Primary)
  • Indications Ischaemic pain; Neuropathic pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Jan 2015 Accrual to date is 110% according to United Kingdom Clinical Research Network.
    • 14 Jan 2015 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network record.
    • 29 Dec 2012 Additional lead trial centre identified as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top